Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AndroGel 1.62% ABPM Study in Hypogonadal Men
NCT04274894Phase 4Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of AndroForte in Hypogonadism, sponsored by AbbVie Inc. Primary endpoint: Systolic Blood Pressure at 16 weeks. Started May 2020; status: completed.
02
Drugs
AndroForte
03
Conditions
Hypogonadism
Beyond the preview
Go deeper on NCT04274894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04274894.